About Candel

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. However, most patients do not achieve stable disease remission with currently available immunotherapies.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications.


Candel’s products are designed to significantly improve survival while maintaining quality of life – from early- to late-stage disease.

Our PURPOSE

to save, extend and improve the lives of patients through oncolytic viral immunotherapies.


Our PLAN

to harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.

OUR LEADERSHIP

is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on excellent science, and our experienced team is helping translate its full promise to patients.

BOARD OF DIRECTORS

RESEARCH ADVISORY BOARD

SCIENTIFIC ADVISORS

Charu Aggarwal, M.D., MPH
Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania

Steven M. Albelda, M.D.
Professor of Medicine and Vice Chief, Pulmonary, Allergy and Critical Care Division, Thoracic Research Laboratory, University of Pennsylvania​

Mark Bloomston, M.D.
Medical Director, South Florida Surgical Oncology

E. Antonio Chiocca, M.D., Ph.D.
Chair, Department of Neurosurgery Brigham and Women’s Hospital and Professor, Harvard Medical School

Scott Eggener, M.D.
Professor of Surgery and Radiology, Vice Chair of Urology, Director High Risk and Advanced Prostate Cancer Clinic, University of Chicago

Adam Kibel, M.D.
Chief, Division of Urology Brigham and Women’s Hospital and Professor, Harvard Medical School

Tri Le, M.D.
Assistant Professor, Medicine, Hematology and Oncology, University of Virginia

Daniel H. Sterman, M.D.
Professor and Director, Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health

Patrick Y. Wen, M.D.
Director, Center for Neuro-Oncology Dana-Farber Cancer Institute and Professor, Neurology, Harvard Medical School

Sunil Singhal, M.D.
Assistant Professor of Surgery, University of Pennsylvania School of Medicine

© 2021 by Candel Therapeutics